AI-generated analysis. Always verify with the original filing.
Immunic, Inc. entered into a private placement securities purchase agreement on February 12, 2026, to issue warrants for up to $200 million in gross proceeds, with potential for an additional $200 million upon exercise. The company also appointed a new director and entered into a royalty purchase agreement exchanging certain existing warrants for future royalty interests.
Event Type
Disclosure
Mandatory
Variant
8-K
. Entry into a Material Definitive Agreement . Private Placement Securities Purchase Agreement On February 12, 2026, Immunic Inc. (the “ Company ”) entered into
. The Warrants are being sold and, upon exercise the securities underlying the Warrants, will be issued without registration under the Securities Act, in relian
. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Appointment of Director On February 12, 2026, the boar
Other Events. On February 13, 2026, the Company issued a press release announcing, among other things, the commencement of the Offering, a copy of which is atta
. Financial Statements and Exhibits Exhibit Description 4.1 Form of Pre-Funded Warrant 4.2 Form of Common Warrant 10.1 Form of Securities Purchase Agreement, da
Thor Nagel
Effective: 2026-02-12
Following recommendation of the Nominating and Corporate Governance Committee
Material Agreement